Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience
Journal Title: Balkan Medical Journal - Year 2018, Vol 35, Issue 6
Abstract
Background: Thrombotic thrombocytopenic purpura is a potentially life-threatening condition. Although the introduction of therapeutic plasma exchange has reduced mortality rates from over 90% to 10%-20%, approximately 40% of patients relapse, and outcomes may be fatal in refractory patients. There is clearly a need for additional therapeutic approaches. Aims: To describe the outcomes of relapsed/refractory thrombotic thrombocytopenic purpura patients treated with vincristine as an adjunct to therapeutic plasma exchange. Study Design: Cross-sectional study. Methods: The medical records of all relapsed/refractory patients with thrombotic thrombocytopenic purpura treated with vincristine adjunct to therapeutic plasma exchange between October 2000 and December 2016 were retrospectively reviewed. Diagnosis of thrombotic thrombocytopenic purpura was based on clinical history, physical examination, and laboratory examinations. Patient demographics, laboratory findings, initial date and duration of therapeutic plasma exchange, dosage and time of administration of vincristine, and outcomes were recorded. Results: The study included 15 patients [median age: 37 years (range: 26-65); 7 women and 8 men] with either relapsed or refractory thrombotic thrombocytopenic purpura who were treated with vincristine as an adjunct to therapeutic plasma exchange for a total of 22 episodes. Eighty-seven percent of patients achieved remissions in 20 of 22 episodes, with a median duration of remission of 29.5 months (range: 3-105). After a median follow-up of 55 months, 11 patients were alive. Vincristine was well tolerated with no safety concerns. Conclusion: Vincristine offers a reasonable option for the treatment of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Further studies evaluating vincristine in the front-line setting and in the relapsed/refractory setting are needed to validate the role of vincristine in thrombotic thrombocytopenic purpura patients.
Authors and Affiliations
Seniz Öngören, Ayşe Salihoğlu, Tuğçe Apaydın, Sevil Sadri, Ahmet Emre Eşkazan, Muhlis Cem Ar, Tuğrul Elverdi, Zafer Başlar, Yıldız Aydın, Teoman Soysal
Keywords
Related Articles
- EP ID EP420839
- DOI 10.4274/balkanmedj.2017.1215
- Views 76
- Downloads 0
High-Resolution Computed Tomography and Pulmonary Function Findings of Occupational Arsenic Exposure in Workers
Background: The number of studies where non-malignant pulmonary diseases are evaluated after occupational arsenic exposure is very few. Aims: To investigate the effects of occupational arsenic exposure on the lung by hig...
Non-thrombotic Pulmonary Embolism Due to Liver Hydatic Cyst: A Case Report
Background: A non-thrombotic pulmonary embolism is defined as embolization to the pulmonary circulation. It may be caused by microorganisms, foreign bodies, different cell types or gas in the pulmonary circulation. Pulmo...
Pediatric Mercury Intoxication Mimicking Pheochromocytoma
.
Congenital Heart Disease in Asymptomatic Neonates with Extra-Cardiac Malformations and Genetic Disorders
.
The Effects of Irisin on Nω-Nitro-L-arginine Methyl Ester Hydrochloride-Induced Hypertension in Rats
Background: The cause of about 95% of hypertension, an important public health problem, is unknown. Intensive studies are underway to understand the physiopathology of hypertension. Irisin, a newly discovered hormone, ha...